<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00257569</url>
  </required_header>
  <id_info>
    <org_study_id>104913</org_study_id>
    <nct_id>NCT00257569</nct_id>
  </id_info>
  <brief_title>Study Of Atopic Dermatitis In Pediatrics</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of Cetirizine Dry Syrup in Children -Suffering From Atopic Dermatitis-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To verify of cetirizine dry syrup to ketotifen dry syrup in the change in the severity of&#xD;
      pruritus of the treatment period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in the severity of pruritus</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>-changes in the total pruritus score -daily main pruritus score -improvement of area with pruritus -patient global improvement -Cetirizine serum concentrations -Adverse events</measure>
  </secondary_outcome>
  <enrollment>278</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetirizine Dry Syrup</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children diagnosed as atopic dermatitis&#xD;
&#xD;
          -  Giving informed consent&#xD;
&#xD;
          -  Children who have 2 grades or more pruritus score.&#xD;
&#xD;
          -  Children who require the treatment with external steroid preparation other than face&#xD;
             and head.&#xD;
&#xD;
          -  Children with a pruritus severity of 2.&#xD;
&#xD;
          -  Mild or severe on the fist day of the treatment period.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  have spastic disease such as epilepsy&#xD;
&#xD;
          -  have a history of drug hypersensitivity&#xD;
&#xD;
          -  are lactating or possibly pregnant female Children&#xD;
&#xD;
          -  have a skin infection, or with zooparasite such as scabies and pediculosis&#xD;
&#xD;
          -  cannot avoid the use of external steroid classified into strong, strongest or very&#xD;
             strong&#xD;
&#xD;
          -  have eczematous otitis externa with perforation in the eardrum&#xD;
&#xD;
          -  have dermal ulcer, or profound heat burn or frostbite of the severity higher than the&#xD;
             grade 2&#xD;
&#xD;
          -  have asthma that requires the treatment with corticosteroid&#xD;
&#xD;
          -  have pruritus only on face and head&#xD;
&#xD;
          -  have inappropriate complication of dermal disorder that may influence on the&#xD;
             evaluation of the study drug&#xD;
&#xD;
          -  are undergoing specific desensitization therapy or immunomodulation therapy or&#xD;
             phototherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
    </facility>
  </location>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>November 21, 2005</study_first_submitted>
  <study_first_submitted_qc>November 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2005</study_first_posted>
  <last_update_submitted>May 3, 2013</last_update_submitted>
  <last_update_submitted_qc>May 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetirizine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

